New method at the Danish Medicines Council gives Merck hope of a Danish breakthrough for its sclerosis treatment
![Enrique Álvarez Fernández became head of Merck in Denmark in June 2019. | Foto: Merck/PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article11983444.ece/ALTERNATES/schema-16_9/doc79gi3kf8a7n5nvukfpi.jpg)
A completely new approach to evaluating the effect of treatments, as well as new data on side effects, may be the key that unlocks the Danish multiple sclerosis market for German pharmaceutical company Merck's big growth hope, Mavenclad.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.